•  
  •  
  •  
  •  

2026-07-20 23:13:21

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • RITES & MECON sign MoU to explore business avenues
  • California Software Company Q1 FY27 Results: Consolidated Net Profit Surges 2,071% YoY to ₹4.19 Crore; Revenue Up 329%
  • Swastika Investmart Q1 FY27 Results: Consolidated Net Profit Rises 14.5% YoY to ₹3.76 Crore; Operational Revenue Up 10%
  • Golden Legand Leasing and Finance Q1 FY27 Results: Net Profit Drops 88.8% YoY to ₹54.89 Lakh Amid Top-Line Contraction
  • Authum Investment & Infrastructure Q1 FY27 Net Profit Rises 17.5% YoY to ₹1,108 Crore; Total Income Up 21.3%

Keywords Selected:  AlkemLaboratories

Stock Report

  • Alkem Laboratories becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350
  • US FDA Inspection at Alkem Laboratories Ltd's CRO facility located at Taloja
  • US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Amaliya, Daman
  • Alkem launches A to Z Daily, an everyday multivitamin supplement for body and mind
  • Alkem Laboratories Doubles Investment for Ujjain Greenfield Facility
  • USFDA inspection at the manufacturing facility of Enzene Biosciences Limited
  • GMP Inspection by Malta Medicines Authority at Alkem's manufacturing facility located at Daman, India
  • GMP Inspection by Ministry of Health, Armenia at Alkem's manufacturing facility located at Sikkim, India
  • Alkem launches probiotic 'DSS', the original De Simone formulation, in India for gut health management
  • Alkem Foundation and IIT Bombay announce strategic collaboration to set up advanced research centre for immunotherapeutics and regenerative medicines
  • Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer
  • Alkem launches Olesoft Trucera, an advanced ceramide-boosting moisturizing lotion for skin barrier repair
  • Alkem Medtech to acquire 100% stake of Bombay Ortho
  • US FDA Inspection at Alkem Laboratories Ltd's Bioequivalence Center located at Taloja
  • Alkem Laboratories launches generic empagliflozin and its combinations in India under the brand name 'Empanorm'
  • Alkem Laboratories enters into a licensing agreement with US-based Sonnet BioTherapeutics
  • Alkem Laboratories denies claims of Pan-D, Clavam 625 batches being not-of-standard quality
  • Closure of US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Baddi, India
  • Alkem Laboratories Ltd receives Form 483 with 10 observations for Baddi facility
  • Closure of US FDA Inspection at Alkem Laboratories Ltd's API manufacturing facility located at Mandva
  • Alkem Laboratories Ltd updates on sale of S&B Pharma LLC's facility
  • Alkem Laboratories Ltd receives 3 observations from USFDA for API manufacturing facility located at Mandva
  • BIOSERGEN, ALKEM collaborate to develop anti-infective for severe fungal infections
  • Alkem Laboratories Ltd recommends final dividend of Rs. 10

Latest Post

  • RITES & MECON sign MoU to explore business avenues
  • California Software Company Q1 FY27 Results: Consolidated Net Profit Surges 2,071% YoY to ₹4.19 Crore; Revenue Up 329%
  • Swastika Investmart Q1 FY27 Results: Consolidated Net Profit Rises 14.5% YoY to ₹3.76 Crore; Operational Revenue Up 10%
  • Golden Legand Leasing and Finance Q1 FY27 Results: Net Profit Drops 88.8% YoY to ₹54.89 Lakh Amid Top-Line Contraction
  • Authum Investment & Infrastructure Q1 FY27 Net Profit Rises 17.5% YoY to ₹1,108 Crore; Total Income Up 21.3%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025